CTIS2023-509571-16-00招募中1 期
A Phase 1b/2 Open-Label, Multicenter Study of RMC-6291 in Combination with Pembrolizumab with or without Chemotherapy, in Patients with KRASG12C-Mutated Solid Tumors – Subprotocol A - RMC-LUNG-101A
Revolution Medicines Inc.0 个研究点目标入组 345 人开始时间: 2024年2月29日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 345
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1. = 18 years of age and signed the Informed Consent Form (ICF) 2. Patients that have solid tumor with KRAS mutation. 3. Patients that have received prior cancer treatment. 4. Patients that have at least one tumor lesion (an area of abnormal tissue) that can be measured. 5. Patients that have adequate organ function (bone marrow, liver, kidney).
排除标准
- •1. Participants that have primary brain and spinal cord tumor. 2. Participants thathave gastrointestinal problems that may affect absorption of RMC-6291. 3. Participants thathad any major surgery in the last 4 weeks. 4. Participants thathave any other medical condition that may interfere with the study drugs. 5. Participants that have previously taken targeted therapy for KRAS mutation.
研究者
相似试验
招募中
1 期
A study of RMC-6236 in combination with pembrolizumab in participants with nonsmallcell lung cancer with certain mutations -Subprotocol Bung CancerMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-509572-42-00Revolution Medicines Inc.405
进行中（未招募）
1 期
A clinical study of the compound MCS110 in combination with the compound PDR001 in patients with advanced cancersEUCTR2016-000210-29-DEovartis Pharma Services AG175
进行中（未招募）
1 期
A clinical study of the compound MCS110 in combination with the compound PDR001 in patients with advanced cancersEUCTR2016-000210-29-FRovartis Pharma Services AG175
进行中（未招募）
1 期
A clinical study of the compound MCS110 in combination with the compound PDR001 in patients with advanced cancersadvanced malignanciesMedDRA version: 18.1Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2016-000210-29-ESovartis Farmacéutica, S.A.141
进行中（未招募）
1 期
A clinical study of the compound MCS110 in combination with the compound PDR001 in patients with advanced cancersadvanced malignanciesMedDRA version: 21.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2016-000210-29-FIovartis Pharma Services AG175